AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

THE LAWSUIT: A class action securities lawsuit was filed against AstraZeneca PLC that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February ...

SAN DIEGO, CA / ACCESSWIRE / January 9, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

UBS has recently raised AstraZeneca PLC (AZN) stock to Neutral rating, as announced on November 20, 2024, according to Finviz. Earlier, on November 6, 2024, Deutsche Bank had raised the stock from a ...

Shares of AstraZeneca PLC AZN rose 2.18% to £109.88 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.83% to 8,319.69.

NDAQ:AZN) The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against AstraZeneca PLC ...

The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC . Shareholders who purchased shares of AZN ...

AstraZeneca's Lynparza receives NICE approval for treating advanced breast cancer in England and Wales, backed by OlympiAD ...

The latest trading day saw Astrazeneca (AZN) settling at $66.58, representing a -0.09% change from its previous close.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...